Onco BCG 40mg Injection contains Bacillus Calmette-Guerin (BCG) strain, a live attenuated vaccine primarily used as an immunotherapeutic agent in the treatment of superficial bladder cancer. The 40mg dosage is specifically formulated for intravesical administration, where it stimulates a localized immune response against malignant cells within the bladder mucosa. BCG works by activating the body's immune system, inducing a complex cascade of cellular and cytokine-mediated mechanisms that target and destroy cancerous cells. It is indicated for the treatment of carcinoma in situ and for the prophylaxis of recurrence and progression in patients with high-risk non-muscle invasive bladder cancer following transurethral resection. Onco BCG 40mg Injection should be administered under strict aseptic conditions by trained healthcare professionals, with careful patient selection and monitoring to minimize adverse effects such as cystitis, hematuria, and systemic BCG infection. Contraindications include active urinary tract infections, gross hematuria, and immunosuppression. Proper patient counseling regarding potential side effects and adherence to treatment protocols is essential to optimize therapeutic outcomes. Onco BCG 40mg Injection represents a critical component in bladder cancer management, offering a targeted immunotherapeutic approach to reduce recurrence and improve long-term prognosis.